Equities analysts expect Zymeworks Inc (NYSE:ZYME) to announce $7.50 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Zymeworks’ earnings. Zymeworks posted sales of $2.05 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 265.9%. The firm is expected to issue its next quarterly earnings report on Tuesday, November 5th.

On average, analysts expect that Zymeworks will report full-year sales of $24.78 million for the current fiscal year, with estimates ranging from $12.00 million to $32.83 million. For the next year, analysts anticipate that the firm will report sales of $34.63 million, with estimates ranging from $33.00 million to $36.25 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Zymeworks.

Zymeworks (NYSE:ZYME) last released its quarterly earnings data on Friday, August 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.06). The business had revenue of $7.88 million for the quarter, compared to analysts’ expectations of $7.25 million. Zymeworks had a negative return on equity of 24.44% and a negative net margin of 102.78%.

Several equities analysts have recently weighed in on the stock. Deutsche Bank assumed coverage on shares of Zymeworks in a research report on Thursday, July 18th. They set a “buy” rating and a $34.00 price objective for the company. Barclays raised their price objective on shares of Zymeworks from $15.00 to $23.00 and gave the company an “equal weight” rating in a research report on Monday, August 5th. Zacks Investment Research upgraded shares of Zymeworks from a “hold” rating to a “strong-buy” rating and set a $26.00 price objective for the company in a research report on Thursday, June 27th. Canaccord Genuity set a $23.00 price objective on shares of Zymeworks and gave the company a “buy” rating in a research report on Friday, May 3rd. Finally, Raymond James set a $36.00 price objective on shares of Zymeworks and gave the company an “outperform” rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $30.67.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its position in Zymeworks by 42.3% during the second quarter. BlackRock Inc. now owns 1,679 shares of the company’s stock valued at $37,000 after acquiring an additional 499 shares in the last quarter. Advisor Group Inc. raised its position in shares of Zymeworks by 42.7% in the second quarter. Advisor Group Inc. now owns 1,806 shares of the company’s stock valued at $40,000 after purchasing an additional 540 shares during the period. Bank of Montreal Can raised its position in shares of Zymeworks by 36.1% in the first quarter. Bank of Montreal Can now owns 5,960 shares of the company’s stock valued at $96,000 after purchasing an additional 1,580 shares during the period. A.R.T. Advisors LLC bought a new position in shares of Zymeworks in the second quarter valued at approximately $201,000. Finally, Jane Street Group LLC bought a new position in shares of Zymeworks in the second quarter valued at approximately $211,000. 30.43% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:ZYME traded up $1.39 on Thursday, reaching $26.39. 373,700 shares of the company’s stock were exchanged, compared to its average volume of 150,028. The firm has a market capitalization of $979.44 million, a price-to-earnings ratio of -20.94 and a beta of 1.47. Zymeworks has a fifty-two week low of $10.72 and a fifty-two week high of $27.16. The business’s 50-day moving average is $23.80 and its two-hundred day moving average is $18.81. The company has a quick ratio of 9.07, a current ratio of 9.07 and a debt-to-equity ratio of 0.02.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors.

Featured Article: Quantitative Easing

Get a free copy of the Zacks research report on Zymeworks (ZYME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zymeworks (NYSE:ZYME)

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.